On May 7, 2025, the American College of Rheumatology (ACR) released the full guideline for diagnosing, monitoring, and treating lupus nephritis (LN), which appeared in Arthritis & Rheumatology.

Rapid reduction of glucocorticoid (GC) doses to 7.5 mg/day or less within 6 months may not worsen renal outcomes or increase relapse in patients with proliferative lupus nephritis (LN), recent study ...

Belimumab, a monoclonal antibody, added to standard therapy may treat a broader range of patients with lupus nephritis than previously appreciated.

Current treatment paradigms for lupus nephritis offer significant room for ... voclosporin and a drug in the calcineurin inhibitor class can lead to positive outcomes, she said that an end-of ...

The finding might ... For patients with active lupus nephritis, obinutuzumab, a humanized type II anti-CD20 monoclonal antibody plus standard therapy is more efficacious for providing a complete ...

No writing assistance was utilized in the production of this manuscript. Lupus nephritis (LN) is one of the most serious complications of systemic lupus erythematosus. Immunological features ...

Although the unpurified extract is reportedly an effective treatment for lupus nephritis in mice ... and tripdiolide (88.2%) groups than in the control group (35.7%). Serum levels of antibodies ...

Lupus nephritis (LN) has a strong prognostic impact in patients with SLE ... The PS-adjusted HR for CRR was 19 (95% CI 2.2 to 160.9). No patients with class V LN in the LCN group progressed to CKD, vs ...

Renal disease is a major cause of mortality and morbidity in systemic lupus erythematosus. Among the histological classes of lupus nephritis ... change in histological class and determine residual ...

Objective Lupus nephritis (LN) is characterised by renal endothelial dysfunction ... All patients with LN flare had active, class IV nephritis by ISN/RPS criteria. Complement levels were lower (13±7 ...

Kidney inflammation caused by SLE is referred to as lupus nephritis (LN), and it is estimated that between 40% and 50% of all SLE patients will develop LN that requires treatment over the course ...

The US regulator has started a review of Roche's supplemental biologics license application (BLA) for Gazyva/Gazyvaro (obinutuzumab) as a treatment for lupus nephritis, with a decision expected in ...